Drugs / CD3-MUC1 Bispecific Antibody
CD3-MUC1 Bispecific Antibody
also known as
anti-CD3-MUC1 bispecific antibody
Other / unclassified targets MUC1
Trials 0
Also used as a comparator or background therapy in 7 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 27 trials | ||||||
| Phase 2 | NCT03524261 Comparator | May 2019 → Apr 2020 | breast cancer | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded |
| Phase 2 | NCT03509298 Comparator | Apr 2018 → May 2020 | digestive system carcinoma | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded |
| Phase 2 | NCT03540199 Comparator | Apr 2018 → May 2020 | kidney cancer | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded |
| Phase 2 | NCT03554395 Comparator | Apr 2018 → May 2020 | gastric cancer | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded |
| Phase 2 | NCT03524274 Comparator | Apr 2018 → May 2020 | colorectal cancer | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded |
| Phase 2 | NCT03501056 Comparator | Mar 2018 → May 2020 | lung cancer | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded |
| Phase 2 | NCT03484962 Comparator | Mar 2018 → May 2020 | liver cancer | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD3-MUC1 Bispecific Antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03524274 ↗ |
| Known as | anti-CD3-MUC1 bispecific antibody | “This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced liver cancer.” NCT03484962 ↗ |
| Modality | Other / unclassified | “bispecific antibody of anti-CD3/MUC1” NCT03524261 ↗ |
| Target | MUC1 | “bispecific antibody of anti-CD3/MUC1” NCT03501056 ↗ |